- Home
- BLRX vs MEIP Comparison
BLRX vs MEIP Comparison
Compare BLRX & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- MEIP
- Stock Information
- Founded
- BLRX 2003
- MEIP 2000
- Country
- BLRX Israel
- MEIP United States
- Employees
- BLRX N/A
- MEIP N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- BLRX Health Care
- MEIP Health Care
- Exchange
- BLRX Nasdaq
- MEIP Nasdaq
- Market Cap
- BLRX 17.3M
- MEIP 16.3M
- IPO Year
- BLRX 2011
- MEIP 2003
- Fundamental
- Price
- BLRX $0.10
- MEIP $2.87
- Analyst Decision
- BLRX Strong Buy
- MEIP Hold
- Analyst Count
- BLRX 2
- MEIP 2
- Target Price
- BLRX $5.50
- MEIP $7.00
- AVG Volume (30 Days)
- BLRX 18.8M
- MEIP 36.2K
- Earning Date
- BLRX 11-25-2024
- MEIP 02-11-2025
- Dividend Yield
- BLRX N/A
- MEIP N/A
- EPS Growth
- BLRX N/A
- MEIP N/A
- EPS
- BLRX N/A
- MEIP N/A
- Revenue
- BLRX $21,991,000.00
- MEIP N/A
- Revenue This Year
- BLRX N/A
- MEIP N/A
- Revenue Next Year
- BLRX N/A
- MEIP $300.00
- P/E Ratio
- BLRX N/A
- MEIP N/A
- Revenue Growth
- BLRX N/A
- MEIP 33.76
- 52 Week Low
- BLRX $0.08
- MEIP $2.30
- 52 Week High
- BLRX $1.44
- MEIP $4.97
- Technical
- Relative Strength Index (RSI)
- BLRX 28.83
- MEIP 66.22
- Support Level
- BLRX $0.23
- MEIP $2.56
- Resistance Level
- BLRX $0.14
- MEIP $2.78
- Average True Range (ATR)
- BLRX 0.03
- MEIP 0.15
- MACD
- BLRX -0.00
- MEIP 0.04
- Stochastic Oscillator
- BLRX 6.93
- MEIP 100.00
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.